Why is ABEO down?
Down 39% on Nov 9, and still 42% under its Nov 6 close.
- Its Nov 9 results:
−3Long-term trend
Down 39% on Nov 9, and still 42% under its Nov 6 close.
−3Long-term trend
ABEO's Quality Score rose 1 point on Fri, Nov 20, to -5. More shares traded than usual.
Follow ABEO's trial news. Pro members can get an alert when Abeona Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 12.2% a day with no profit behind it |
| Latest filing | S-3, Nov 18 |
After its last 4 reports it closed -14.3% on average, higher 1 of 4 times.
About 8 quarters
No shelf registration or at-the-market program on file in the last three years.
Director Faith L. Charles bought 15,000 shares on Nov 13. 31 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ABEO is #189 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 189 |
Expected to report Tue Mar 16, before the open (in 115 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $13.5M.
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $13.5M | $11.4M | $0 |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 9)
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -13.2% | -39.1% | -42.0% |
| Aug 13, 2026 | -18.4% | -14.9% | -17.8% |
| May 13, 2026 | +2.3% | +0.5% | -9.9% |
Sales grew in two of the last four years, to $3.5M in 2023. It turned a profit in 2025 after a loss in 2023.
RSI 26.7, MACD below signal, below both averages. Not scored.
One insider bought $34K across 1 filing, and 7 insiders sold $1.7M across 18 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ABEO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
ABEO scores -5 today, which Breakaway calls Poor. It is #189 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 39% on Nov 9, and still 42% under its Nov 6 close. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ABEO scores -5 today, which Breakaway calls Poor (below zero). That is #189 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABEO's -5.
One insider bought $34K across 1 filing, and 7 insiders sold $1.7M across 18 filings, in the last 6 months. The newest is Faith L. Charles, Director, who bought $34K on Nov 13. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.